To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...

Gilead Sciences's GILD short percent of float has risen 6.47% since its last report. The company recently reported that it ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

It has been about a month since the last earnings report for Gilead Sciences (GILD). Shares have added about 10.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target hoisted by equities researchers at Morgan Stanley from $123.00 to $130.00 in a research note issued to investors on ...

Josh Brown, CEO of Ritholtz Wealth Management, said during a program on CNBC last month that he’s paying attention to Gilead Sciences Inc (NASDAQ:GILD).

U.S. investment bank Goldman Sachs (GS) has published a list of stocks that it feels can help investors weather the current ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...